Flex Pharma demonstrates efficacy of synthesized single and combination agents in reducing human muscle cramps
Presentation at the European Committee for Treatment and Research of Multiple Sclerosis
Flex Pharma will present data demonstrating the efficacy of purified, GMP-synthesized single molecules, as well as combinations of two individual molecules, of TRPA1 and TRPV1 agonists, in significantly reducing human muscle cramp intensity in its electrically induced cramp model at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Barcelona, Spain at 9:45am ET on 8 October 2015.
The abstract titled, “TRPV1 and TRPA1 activators reduce muscle cramping: Potential new treatment for MS symptoms,” will be presented by neurologist and Flex Pharma Chief Medical Officer, Dr Tom Wessel, who served as the medical lead for three products approved in US: Razadyne, Lunesta and Ampyra.
“By testing the most potent TRPA1 and TRPV1 agonists and demonstrating enhanced efficacy with purified single agent and doublet combinations compared to the original proprietary formulation, we have made significant progress in our product development efforts,” said Dr Wessel. Utilizing the established electrically induced model in normal healthy volunteers (n=9), the purified single molecules, as well as combinations of two individual molecules, of GMP-synthesized TRPA1 and TRPV1 agonists, significantly reduced cramp intensity relative to vehicle control (p<0.01) and compared to the original proprietary formulation of extract mixture (p<0.05).
Nobel laureate and Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair, Dr Rod MacKinnon noted: “We are excited to be on the forefront of investigating chemical neuro stimulation as a novel and perhaps generally applicable method to treat disorders of cramping and spasms stemming from alpha motor neuron hyperexcitability.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance